Similar articles for PMID: 25672584

Year	Number of Results
1949	1
1991	1
1997	1
1999	1
2000	1
2001	1
2003	4
2004	6
2005	3
2006	8
2007	8
2008	1
2009	5
2010	18
2011	14
2012	16
2013	10
2014	9
2015	10
2016	7
2017	13
2018	6
2019	8
2020	5
2021	6
2022	5
2023	1
2024	0

1

The Frequency of and Risk Factors for the Use of Bisphosphonates in the Adjuvant Setting of Primary Breast Cancer in Germany.

Fick EM, Katalinic A, Waldmann A. Fick EM, et al. Cancer Res Treat. 2015 Oct;47(4):747-56. doi: 10.4143/crt.2014.099. Epub 2015 Jan 5. Cancer Res Treat. 2015. PMID: 25672584 Free PMC article.

2

Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study.

Kremer R, Gagnon B, Meguerditchian AN, Nadeau L, Mayo N. Kremer R, et al. J Natl Cancer Inst. 2014 Oct 2;106(11):dju264. doi: 10.1093/jnci/dju264. Print 2014 Nov. J Natl Cancer Inst. 2014. PMID: 25278509

3

Bisphosphonates in adjuvant setting for breast cancer: a review of the meta-analysis of bisphosphonates' effects on breast cancer recurrence presented in December 2013 at San Antonio Breast Conference.

Costa L. Costa L. Curr Opin Support Palliat Care. 2014 Dec;8(4):414-9. doi: 10.1097/SPC.0000000000000101. Curr Opin Support Palliat Care. 2014. PMID: 25319273 Review.

4

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.

Eisen A, Somerfield MR, Accordino MK, Blanchette PS, Clemons MJ, Dhesy-Thind S, Dillmon MS, D'Oronzo S, Fletcher GG, Frank ES, Hallmeyer S, Makhoul I, Moy B, Thawer A, Wu JY, Van Poznak CH. Eisen A, et al. J Clin Oncol. 2022 Mar 1;40(7):787-800. doi: 10.1200/JCO.21.02647. Epub 2022 Jan 18. J Clin Oncol. 2022. PMID: 35041467

5

Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.

Ito K, Blinder VS, Elkin EB. Ito K, et al. J Clin Oncol. 2012 May 1;30(13):1468-75. doi: 10.1200/JCO.2011.38.7001. Epub 2012 Feb 27. J Clin Oncol. 2012. PMID: 22370313

6

Role of Bisphosphonates in Breast Cancer Therapy.

Goldvaser H, Amir E. Goldvaser H, et al. Curr Treat Options Oncol. 2019 Mar 14;20(4):26. doi: 10.1007/s11864-019-0623-8. Curr Treat Options Oncol. 2019. PMID: 30874905 Review.

7

Bone-modifying agents as adjuvant therapy for early-stage breast cancer.

Figueroa-Magalhães MC, Miller RS. Figueroa-Magalhães MC, et al. Oncology (Williston Park). 2012 Oct;26(10):955-62. Oncology (Williston Park). 2012. PMID: 23176008 Free article. Review.

8

American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.

Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, Yee G, Biermann JS, Chlebowski RT, Pfister DG. Hillner BE, et al. J Clin Oncol. 2000 Mar;18(6):1378-91. doi: 10.1200/JCO.2000.18.6.1378. J Clin Oncol. 2000. PMID: 10715310

9

Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.

Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, Keane M, Gil M, Burkinshaw R, Grieve R, Barrett-Lee P, Ritchie D, Liversedge V, Hinsley S, Marshall H; AZURE investigators. Coleman R, et al. Lancet Oncol. 2014 Aug;15(9):997-1006. doi: 10.1016/S1470-2045(14)70302-X. Epub 2014 Jul 15. Lancet Oncol. 2014. PMID: 25035292 Clinical Trial.

10

[The role of bisphosphonates of adjuvant therapy in breast cancer].

Gálvez-Muñoz E, Rodríguez-Lescure Á. Gálvez-Muñoz E, et al. Med Clin (Barc). 2010 Jun 12;135(2):70-4. doi: 10.1016/j.medcli.2009.10.013. Med Clin (Barc). 2010. PMID: 20022069 Review. Spanish.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

151 results

Results by year